

Arenavirus

Arenavirus genome includes two ambisense RNA segments that encode only four viral proteins: the envelope glycoprotein precursor, nucle-ocapsid protein, matrix zinc-binding (Z) protein and the large (L) RNA-dependent RNA polymerase (RdRp). The L protein is a multi-domain machinery with both transcription and replication activities. Similar to other segmented negative-sense RNA viruses (sNSVs), the replication of arenavirus genome is de novo initiated and involves a complementary RNA (cRNA) intermediate, whereas the transcription process presumably requires a host mRNA-derived primer captured by the viral polymerase through cap snatching.


Arenaviruses can cause severe haemorrhagic fever and neurological diseases in humans and other animals, exemplified by Lassa mammarenavirus, Machupo mammarenavirus and lymphocytic choriomeningitis virus, posing great threats to public health. These viruses encode a large multi-domain RNA-dependent RNA polymerase for transcription and replication of the viral genome. Viral polymerases are one of the leading antiviral therapeutic targets.

Arenavirus Inhibitors & Activators

(E)-LHF-535

Cat. No.: HY-112762A

(E)-LHF-535 is the E-isomer of LHF-535. LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC₅₀s of <1 μ M, <1 μ M, <1 μ M, and 1-10 μ M for Lassa, Machupo, Junin, and VSVg virus, respectively.



Purity: 99 71%

Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GP(33-41)

Cat. No.: HY-P0323

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM.

KAVYNFATC

Purity: >98%

Clinical Data: No Development Reported 1 mg, 5 mg, 10 mg

Nucleoprotein (396-404)

(NP 396) Cat. No.: HY-P1571

Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

FQPQNGQFI

Purity: >98%

Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg

ST-193

Cat. No.: HY-101441

ST-193 is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC_{so} values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.



99.86% Purity:

Clinical Data: No Development Reported

Size 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Verrucarin J

(Muconomycin B)

Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species (ROS) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells.



Cat. No.: HY-N10113

Purity: >98%

Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg

5,7-Dihydroxychromone

5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis.



Cat. No.: HY-112762

Cat. No.: HY-N1970

Purity: 99 98%

Clinical Data: No Development Reported

Size: 5 mg, 10 mg

LHF-535

LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC₅₀s of <1 μ M, <1 μ M, <1 μ M, and 1-10 μ M for Lassa, Machupo, Junin, and VSVg virus,

respectively.

Purity: 99 20%

Clinical Data: No Development Reported

10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Retro-2 cycl

(RN 1-001) Cat. No.: HY-114698

Retro-2 cycl (RN 1-001) is a dihydroquinazolinone (DHQZ) inhibitor of retrograde trafficking. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudovirus with IC $_{50}$ s of 54 μ M and 160 μ M, respectively. Antiviral agent.



99.86% Purity:

Clinical Data: No Development Reported

Size 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ST-193 hydrochloride

ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin,

Lassa and Machupo virus with IC₅₀ values of 0.44,

0.62, 1.4 and 3.1 nM, respectively.



Cat. No.: HY-101441A

98.54% Purity:

Clinical Data: No Development Reported

Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg